SSTR2 and non-Hodgkin lymphoma: Moreover, experimental treatment with the cytotoxic somatostatin analog AN-238 strongly inhibited tumor proliferation in a broad variety of SSTR2 positive cancer models such as Non-Hodgkin’s lymphoma [34], malignant melanoma [36], pheochromocytoma [37], endometrial [38], ovarian [39], colon [40] and gastric carcinomas [41] as well as small and non-small cell lung carcinoma [42], [43].